Tuberculosis (TB) is one of the world’s most widespread diseases. Nearly one third of the world’s population has been exposed and 8 million people annually develop active TB. For those who are infected and have latent TB, the treatment is a grueling nine-month-long course with a drug called isoniazid. Now, researchers from McGill University are revealing the results of a multi-national study which shows that four months of treatment with another TB drug, rifampin, is better than the traditional treatment, and confers less liver side effects. Because of this, people are more likely to complete the full course of treatment.
Posts Tagged ‘rifampin’
January 25, 2009


Dr. Steven Chang, the author of DailyDose, is a staff physician with Kosmix RightHealth. Dr. Chang practices Family Medicine at the University of California Davis Medical Center, where his medical interests include both pediatric and geriatric care, public health, gay and lesbian health, and sleep medicine. Dr. Chang trained at the Stanford University affiliated O'Connor Hospital, and was a research fellow at the National Institute of Health. He holds an M.D. from McGill University and a BA in Public Health from Johns Hopkins University.